Figure 4.

Predictor for resistance to immune checkpoint therapy. Figure 4 shows the result of the Fisher’s test identifying a genetic predictor for the resistance to immune checkpoint inhibitor therapy based on the RECIST response classification (progressive disease versus disease control [stable disease, partial response]). Mutations in three genes—EGFR, PTEN and TP53 - were identified as individual predictors for a progressive disease at the first staging. In 89% of cases (16 out of 18), patients with BRAF mutations had previously received BRAF/MEK inhibition before receiving immunotherapy. Together the mutations and the failed BRAF/MEKi pre-therapy predict 82% of the patients as PD (p = 0.007).